Paper - WANFANG MED ONLINE

You Position: Home > Paper

Refractory gastroesophageal reflux disease: Current status and perspectives

( views:34, downloads:0 )

Author:: No author available

Journal Title:: World Chinese Journal of Digestology

Issue:: 33

DOI:: 10.11569/wcjd.v25.i33.2921

Key Word:: 难治性胃食管反流病;诊断;治疗;进展;Refractory gastroesophageal reflux disease;Diagnosis;Treatment;Progress

Abstract： Patients with gastroesophageal reflux disease (GERD)who do not respond to an 8-12 wk course of acidsuppressive therapy with a proton pump inhibitor twice daily,with symptoms such as heartburn and acid reflux symptoms persisting after therapy,can be diagnosed with refractory GERD (RGERD).It is estimated that RGERD accounts for approximately 10％-40％ of all GERD cases.Due to complicated causes,the clinical recognition of RGERD is insufficient.Thanks to the advances in the basic and clinical research of RGERD in recent years,there have been updated consensus guidelines on the diagnosis and treatment of RGERD in America and Asia (including China).This paper reviews the definition,epidemiology,pathophysiology,diagnostic evaluation,and treatment of RGERD.

Reference

[1]刘劲松.难治性胃食管反流病[J].2016,(5).
[2]郝坤艳,姜柳琴,李学良,等.胃食管反流病反流症状程度及相关因素的临床分析[J].2011,(8).
[3]中华医学会消化病学分会.2014年中国胃食管反流病专家共识意见[J].2014,(10).
[4]Rohof,W.O.,Bennink,R.J.,Smout,A.J.P.M.,etc.An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease[J].2013,11(12).
[5]R. Fass,U. Murthy,C. W. Hayden,etc.Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-ce[J].2000,14(12).
[6]Hasler WL.Traditional thoughts on the pathophysiology of irritable bowel syndrome.[J].2011,40(1).
[7]De Santis, Adriano,Scarpellini, Emidio,Tack, Jan,etc.Management of refractory typical GERD symptoms[J].2016,13(5).
[8]Philip O. Katz,Lauren B. Gerson,Marcelo F. Vela.Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease[J].2013,108(3).
[9]Kwong Ming Fock,Nicholas Talley,Khean Lee Goh,etc.Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus[J].2016,(9).
[10]Kim,J.S.,Kim,S.W.,Lee,I.S.,etc.Effect of mosapride combined with esomeprazole improves esophageal peristaltic function in patients with gastroesophageal reflux disease: A study using high resolution manometry[J].2013,58(4).
[11]C. Maydonovitch,M. J. Cossentino,J. M. Lake,etc.Randomised clinical trial: the effect of baclofen in patients with gastro-oesophageal reflux - a randomised prospective study[J].2012,35(9).
[12]David Grundy,Elie D. Al–Chaer,Qasim Aziz,etc.Fundamentals of Neurogastroenterology: Basic Science[J].2006,130(5).
[13]Savarino, E.,de Bortoli, N.,de Cassan, C.,etc.The natural history of gastro-esophageal reflux disease: a comprehensive review[J].2017,30(2).
[14]H. Miwa,T. Minoo,M. Hojo,etc.Oesophageal hypersensitivity in Japanese patients with non-erosive gastro-oesophageal reflux diseases[J].2004,20(s1).
[15]Vieth, Michael,Mastracci, Luca,Vakil, Nimish,etc.Epithelial Thickness is a Marker of Gastroesophageal Reflux Disease[J].2016,14(11).
[16]Hunt, Richard,Armstrong, David,Katelaris, Peter,etc.World Gastroenterology Organisation Global Guidelines GERD Global Perspective on Gastroesophageal Reflux Disease[J].2017,51(6).
[17]Byung-Joon Chun,Dong-Soo Lee.The effect of itopride combined with lansoprazole in patients with laryngopharyngeal reflux disease[J].2013,270(4).
[18]VanZanten,S.V.,Wernersson,B.,Mattsson,H.,etc.Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - A post hoc analysis of 5796 patients[J].2012,36(7).
[19]Dulai GS,Gralnek IM,Spiegel BM,etc.Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials.[J].2006,4(12).
[20]Lascewski DP,Gunaratnam NT,Inadomi J,etc.Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.[J].2006,23(10).
[21]Li-Na, Meng,Shanshan, Chen,Jiande D Z, Chen,etc.Effects of Transcutaneous Electrical Acustimulation on Refractory Gastroesophageal Reflux Disease.[J].2016.
[22]de Schepper, Heiko S.,Weijenborg, Pim W.,Smout, Andre J. P. M.,etc.Effects of Antidepressants in Patients With Functional Esophageal Disorders or Gastroesophageal Reflux Disease: A Systematic Review[J].2015,13(2).
[23]Sugimoto, M.,Shirai, N.,Nishino, M.,etc.Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese[J].2014,70(9).
[24]Ronnie, Fass,Frederick, Cahn,Dennis J, Scotti,etc.Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease.[J].2017,(Spec ).
[25]S, Collins.Putative therapeutic targets in the treatment of visceral hyperalgesia.[J].2004,53 Suppl 2.
[26]Yiping, Wang,Tao, Pan,Qiong, Wang,etc.Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough.[J].2009,(4).
[27]Lars Lundell,Martin Bell,Magnus Ruth.Systematic review:Laparoscopic fundoplication for gastroesophageal reflux disease in partial responders to proton pump inhibitors[J].2014,(3).
[28]Su Jin, Chung,Sang Gyun, Kim,Hyun Chae, Jung,etc.[Clinical practice patterns of gastroenterologists for initial and maintenance therapy in gastroesophageal reflux disease: a nationwide online survey in Korea].[J].2009,54(6).
[29]Odze, Robert D.,Souza, Rhonda F.,Huo, Xiaofang,etc.Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes[J].2016,315(19).
[30]Sugimoto M,Furuta T,Kodaira C.CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole.[J].2009,65(7).
[31]Lee ES,Kim N,Lee SH.Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease.[J].2009,30(2).
[32]William K. Fackler,Tina M. Ours,Michael F. Vaezi,etc.Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough[J].2002,122(3).